We bring you the latest news from the healthcare about the health care in the United Kingdom.

maandag 27 november 2017

Nature Reviews Neurology - Table of Contents alert Volume 13 Issue 12

If you are unable to see the message below, click here to view.
Nature Reviews Neurology

Is your organization planning a scientific event or conference for 2018? 

Looking for a way to increase the number of attendees?

Advertise in the Natureevents Directory 2018.

Available online and in print. Ad close deadline: 4 December, 2017
December 2017 Volume 13 Number 12
Nature Reviews Neurology cover
2016 2-year Impact Factor 20.257 Journal Metrics 2-year Median 15
In this issue
Research Highlights
News and Views
Also this month
 Featured article:
Human models of migraine — short-term pain for long-term gain
Messoud Ashina, Jakob Møller Hansen, Bára Oladóttir á Dunga & Jes Olesen


Recommend to library
Nature Outlook: Women’s health 

From common diseases that affect the sexes differently to conditions that affect only women — and from birth, through the menopause, to old age — there are many challenges in women’s health.

Access the Outlook free online to learn more >>

Produced with support from: Symbiomix Therapeutics, LLC

Multiple sclerosis: A possible link between multiple sclerosis and gut microbiota
Published online: 29 September 2017
p705 | doi:10.1038/nrneurol.2017.142


Alzheimer disease: ApoE4 implicated in tau-mediated neurodegeneration
Published online: 06 October 2017
p706 | doi:10.1038/nrneurol.2017.145


Neurometabolic disease: Gene therapy success for cerebral adrenoleukodystrophy
Published online: 23 October 2017
p706 | doi:10.1038/nrneurol.2017.152


Alzheimer disease: Is p-tau the missing link between insulin resistance and AD?
Published online: 06 November 2017
p706 | doi:10.1038/nrneurol.2017.158


Motor neuron disease: Peripheral immune cell levels correlate with disease progression in ALS
Published online: 13 October 2017
p708 | doi:10.1038/nrneurol.2017.149


Neurodevelopmental disorders: Miniaturized protein offers treatment hopes for Rett syndrome
Published online: 27 October 2017
p708 | doi:10.1038/nrneurol.2017.156




Neuromuscular disease: Tadalafil fails to halt the progression of Duchenne muscular dystrophy | Movement disorders: Patients with spinocerebellar ataxia 38 benefit from DHA supplementation | Parkinson disease: Caffeine and nicotine do not provide symptomatic relief in Parkinson disease

Nature Reviews Neurology
JOBS of the week
Instructor / Assistant / Associate Professor of Neurology
Massachuesetts General Hospital / Harvard Medical School
Postdoctoral fellow / Research Associate in Developmental Neurobiology
SUNY Upstate Medical College
Faculty Position in Neurobiology
Group leader position open at the ICM
ICM Foundation � Brain and spinal cord research Institute
Faculty Position for Neurobiology at NYU Shanghai
More Science jobs from
Nature Reviews Neurology
"World Congress on Neurology and Mental Disorders-2018 "
Rome, Italy
More science events from
Parkinson disease: What goes around comes around: cognitive impairment as prodromal parkinsonism?
Yaroslau Compta & Maria J. Martí

Published online: 10 November 2017
p709 | doi:10.1038/nrneurol.2017.159

Patients with prodromal Parkinson disease (PD) are most likely to respond to disease-modifying strategies. To date, cognitive impairment has been viewed as a complication of late-stage disease, but a longitudinal analysis of data from the Rotterdam cohort raises the possibility that such impairments are also associated with prodromal PD.
Full Text | PDF

Multiple sclerosis: Progressive multifocal leukoencephalopathy risk stratification
Kalliopi Pitarokoili & Ralf Gold

Published online: 17 November 2017
p710 | doi:10.1038/nrneurol.2017.161

A compelling need exists for a more reliable risk evaluation of natalizumab- associated progressive multifocal leukoencephalopathy (PML). A new report proposes a refined protocol that uses updated patient-based data and cumulative risk evaluation to provide an improved assessment of the annual risk of PML for patients positive for JC virus.
Full Text | PDF

Human models of migraine — short-term pain for long-term gain
Messoud Ashina, Jakob Møller Hansen, Bára Oladóttir á Dunga & Jes Olesen

Published online: 06 October 2017
p713 | doi:10.1038/nrneurol.2017.137

In the ongoing search for new and better migraine treatments, human models have a key role in the discovery of novel targets for antimigraine drugs. This Review summarizes existing experimental models of migraine in humans, and describes the development and use of these models in the identification of key molecular pathways, biomarkers and drug targets.
Abstract | Full Text | PDF

Migrainomics — identifying brain and genetic markers of migraine
Dale R. Nyholt, David Borsook & Lyn R. Griffiths

Published online: 17 November 2017
p725 | doi:10.1038/nrneurol.2017.151

The causes of migraine remain unknown despite the high prevalence and societal burden of this disorder. Here, the authors highlight how advances in imaging and genetic studies of migraine provide insights into the underlying mechanisms of this disorder; furthermore, they discuss the potential for genetic and imaging biomarkers to improve our ability to prevent and treat migraine attacks.
Abstract | Full Text | PDF

Achievements and obstacles of remyelinating therapies in multiple sclerosis
Martin Stangel, Tanja Kuhlmann, Paul M. Matthews & Trevor J. Kilpatrick

Published online: 17 November 2017
p742 | doi:10.1038/nrneurol.2017.139

Inadequate remyelination is central to degeneration and disability in patients with multiple sclerosis (MS); however, all currently approved therapies for MS are primarily immunomodulatory. Here, Martin Stangel and colleagues review our current knowledge of remyelination in MS, discuss results from clinical trials of remyelination-enhancing therapies, and evaluate the opportunities for future regenerative treatments.
Abstract | Full Text | PDF

Nature Reviews Disease Primers — Stay updated 

Nature Reviews Disease Primers covers all medical specialties, already having published on more than 120 diseases and disorders since launching in 2015. With such a comprehensive article collection, our e-alerts are the perfect solution to stay updated on the latest content published by the journal. 

Register for the e-alert
Inflammatory CNS disease caused by immune checkpoint inhibitors: status and perspectives
Lidia M. Yshii, Reinhard Hohlfeld & Roland S. Liblau

Published online: 06 November 2017
p755 | doi:10.1038/nrneurol.2017.144

The development of immune checkpoint inhibitors (ICIs) has revolutionized cancer immunotherapy, but these agents carry a high risk of immune-related adverse events. Here, the authors introduce the mechanisms of action of ICIs and review their adverse effects on the CNS, which result in conditions such as paraneoplastic neurological syndromes and multiple sclerosis.
Abstract | Full Text | PDF | Supplementary information

nature events
Natureevents is a fully searchable, multi-disciplinary database designed to maximise exposure for events organisers. The contents of the Natureevents Directory are now live. The digital version is available here.

Find the latest scientific conferences, courses, meetings and symposia on natureevents.com. For event advertising opportunities across the Nature Publishing Group portfolio please contact natureevents@nature.com
More Nature Events
`Nature Reviews Neurology was previously published as Nature Clinical Practice Neurology.

You have been sent this Table of Contents Alert because you have opted in to receive it. You can change or discontinue your e-mail alerts at any time, by modifying your preferences on your nature.com account at: www.nature.com/myaccount
(You will need to log in to be recognised as a nature.com registrant).

For further technical assistance, please contact our registration department

For print subscription enquiries, please contact our subscription department

For other enquiries, please contact our feedback department

Springer Nature | One New York Plaza, Suite 4500 | New York | NY 10004-1562 | USA

Springer Nature's worldwide offices:
London - Paris - Munich - New Delhi - Tokyo - Melbourne
San Diego - San Francisco - Washington - New York - Boston

Macmillan Publishers Limited is a company incorporated in England and Wales under company number 785998 and whose registered office is located at The Campus, 4 Crinan Street, London, N1 9XW.

© 2017 Macmillan Publishers Limited, part of Springer Nature. All Rights Reserved.

Springer Nature